论文部分内容阅读
目的综述比较两种肠促胰岛素肠抑胃肽(GIP)和胰高血糖素样肽1(GLP-1)的研究进展。方法通过查阅国内外最新文献,对肠抑胃肽和胰高血糖素样肽1在其分泌代谢、刺激葡萄糖依赖的胰岛素分泌及在很多表达有其受体的组织和器官中(胰腺、脂肪、骨骼、大脑、胃)参与的重要的生物学过程的研究现状和最新进展进行总结、分析和比较。结果两种肠促胰岛素肠抑胃肽和胰高血糖素样肽1虽然在胰腺、大脑组织中具有部分相似的作用,均能促进β细胞增殖、刺激胰岛素分泌、调节食欲,但是在对胰腺中的胰高血糖素、脂肪组织、骨骼及胃的调节中表现出不同甚至相反的作用。结论利用肠促胰岛素治疗2型糖尿病已成为今后糖尿病药物研究中重要的发展方向,科学地应用肠抑胃肽和胰高血糖素样肽1的生理特性及积极寻找新型的、长效的类似物成为治疗或缓解2型糖尿病的关键。
OBJECTIVE: To review the advances in the study of two gut enterotergic peptides (GIP) and glucagon-like peptide 1 (GLP-1). Methods By referring to the latest literature both at home and abroad, we studied the effects of gut pepstatin and glucagon-like peptide-1 on their secretion and metabolism, stimulated glucose-dependent insulin secretion and in many tissues and organs expressing their receptors (pancreas, fat, Bone, brain, stomach) involved in the important biological processes of research status and the latest developments are summarized, analyzed and compared. Results Both of the two incretin peptides and glucagon-like peptide 1, although partially similar in the pancreas and brain tissue, could promote β-cell proliferation, stimulate insulin secretion and regulate appetite. However, Of glucagon, adipose tissue, bone and stomach show different or even opposite effects. Conclusions The use of incretin to treat type 2 diabetes mellitus has become an important development direction in the future research of diabetes mellitus. Scientific application of the gastrointestinal inhibitory peptides and glucagon-like peptide 1 physiological characteristics and actively looking for new, long-acting analogs Become the key to treating or relieving type 2 diabetes.